With its next-generation CAR-T manufacturing platform, Novartis told JP Morgan Conference delegates it has no plans to move into the allogeneic space. Novartis is one of the pioneers in the chimeric antigen receptor (CAR) T-cell space, bringing the first therapy to market in the US in 2017: Kymriah (tisagenlecleucel), a treatment for B-cell acute lymphoblastic leukemia (ALL). Since then, a handful of other cell-based gene therapy products have been approved by the US Food and Drug Administration (FDA) but all…